What survodutide is
Survodutide is a synthetic, single-chain lipidated peptide designed to activate two receptors: the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It was developed by Boehringer Ingelheim in collaboration with Zealand Pharma under the code BI 456906, and its discovery and preclinical pharmacology are described by Zimmermann and colleagues in a 2022 paper that calls it a "GCG/GLP-1 receptor dual agonist" [1].
The design logic differs from that of the better-known incretin peptides. Where tirzepatide starts from the GIP sequence and semaglutide from GLP-1, survodutide starts from glucagon itself, a 29-residue hormone, and engineers GLP-1 receptor activity into that backbone while keeping glucagon receptor activity. The rationale, set out in the discovery paper, is that glucagon receptor agonism raises energy expenditure and promotes hepatic fat oxidation in the models used, while the GLP-1 component restrains food intake and offsets the tendency of glucagon to raise blood glucose [1]. A fatty-diacid side chain attached to a lysine through a linker binds albumin and extends the half-life to the range that supports once-weekly clinical dosing.
The research material is a white to off-white lyophilised powder. Because the compound is still in development and has no pharmacopoeial monograph, several of the identifiers that appear routinely on the certificates of licensed peptides are not publicly standardised for survodutide. A certificate should state the sequence and expected mass it was tested against, and those figures, rather than a database entry, are the reference for the batch.
| Identifier | Value |
|---|---|
| Development code | BI 456906 |
| Developer | Boehringer Ingelheim, with Zealand Pharma |
| Class | Glucagon/GLP-1 receptor dual agonist |
| Backbone | Glucagon-derived, 29 residues |
| Lipidation | Fatty diacid on a lysine via linker (albumin binding) |
| Half-life in humans | Supports once-weekly dosing |
| Appearance | White lyophilised powder |
| Catalogue sizes | 10 mg |
How the literature describes its mechanism
Glucagon and GLP-1 are products of the same gene, proglucagon, processed differently in the pancreas and the gut. Glucagon acts on the liver to raise glucose output and on adipose tissue and the liver to promote fat oxidation; GLP-1 potentiates glucose-dependent insulin secretion, slows gastric emptying and reduces food intake. Oxyntomodulin, a third proglucagon product, activates both receptors weakly and was the natural prototype for dual agonism. Survodutide is a synthetic pursuit of the same idea with potency and duration that oxyntomodulin lacks.
Zimmermann and colleagues report that BI 456906 is a potent agonist at both human receptors in cell-based cAMP assays, with the potency ratio tuned so that glucagon receptor activity is balanced by sufficient GLP-1 receptor activity to prevent hyperglycaemia in the animal models used [1]. In diet-induced obese mice the compound reduced body weight more than a GLP-1 receptor agonist alone, and the authors attribute the difference to increased energy expenditure from the glucagon component. They also report reduced hepatic fat and markers of liver injury in mouse models of steatohepatitis, which was the basis for taking the compound into a liver-disease trial.
For an in-vitro programme the relevant readouts are cAMP accumulation in cells expressing human GCGR or GLP-1R, receptor selectivity against the GIP receptor (where the compound is reported to be inactive), and hepatocyte lipid-handling assays. Potency figures depend on the cell system and receptor expression level, and the published EC50 values should be treated as a guide to the expected range rather than a specification.
The clinical research record
Survodutide has a phase 2 record in two indications and a phase 3 programme in progress.
In obesity, le Roux and colleagues reported a 46-week phase 2 dose-finding trial in 387 adults with obesity and without diabetes. The highest dose produced a mean weight reduction of about 15 per cent in the planned analysis and about 19 per cent in participants who completed treatment on their assigned dose, against roughly 3 per cent on placebo. Adverse events were mostly gastrointestinal and dose-related, as for the rest of the class [2].
In metabolic dysfunction-associated steatohepatitis (MASH), Sanyal and colleagues reported a 48-week phase 2 trial in 293 adults with biopsy-confirmed disease. Improvement in steatohepatitis without worsening of fibrosis was achieved in up to 62 per cent of participants on survodutide against 14 per cent on placebo, and a larger share showed improvement in fibrosis [3]. The liver result is the clearest demonstration to date of what the glucagon component is intended to add, and it was the basis for the compound receiving breakthrough designations for MASH.
The phase 3 SYNCHRONIZE programme in obesity and the phase 3 LIVERAGE programme in MASH are under way at the time of writing. Until they report, survodutide is a compound with a well-defined mechanism, a substantial phase 2 record, and no licence.
Regulatory status in the United Kingdom
Survodutide has no marketing authorisation in the UK or anywhere else. It is not a medicine, is not controlled under the Misuse of Drugs Act, and is supplied here as a chemical for in-vitro laboratory use under the Terms of Sale. It is not for human or veterinary administration. Purchasers must be 18 or over and are responsible for ensuring their use of the material complies with the laws and institutional rules that apply to them. Our guide to the UK rules on research compounds sets this out in more detail.
In sport, GLP-1 receptor agonists are listed on the WADA Prohibited List under S4.5, hormone and metabolic modulators, and a dual agonist with GLP-1 receptor activity falls within that class.
Handling, storage and stability
Survodutide is supplied lyophilised, sealed under nitrogen in a glass vial with a rubber stopper and an aluminium flip-off crimp. Its handling follows the pattern for lipidated proglucagon-family peptides.
Sealed vial. Store at 2–8 °C for routine use and at −20 °C or below for storage beyond a few months. Protect from light. Allow a refrigerated vial to reach room temperature before opening so that moisture does not condense onto the cake.
Reconstitution. Reconstitute in sterile bacteriostatic water, sterile water, or a buffer appropriate to the assay. Glucagon-derived peptides are notoriously poorly soluble and prone to fibril formation at neutral pH, which is one of the problems the development programme had to solve; the lipidated analogue is more tractable than native glucagon, but it still rewards gentle handling. Add the solvent down the side of the vial, swirl rather than shake, and allow a minute or two for dissolution. The reconstitution calculator gives the volume for a target concentration.
Reconstituted solution. Keep at 2–8 °C, protected from light, and use within 28 days as a conservative practice. Discard a solution that turns cloudy or shows particles, since turbidity in a glucagon-class peptide usually means fibrillation. Do not freeze after reconstitution unless the buffer has been validated for it.
Solubility and surfaces. The fatty-diacid chain makes the molecule amphipathic, so it adsorbs to ordinary polypropylene and to nylon membranes at low concentrations. Use low-binding tubes and PES or PVDF filters. The storage and stability guide covers lipidated peptides in general.
What a sound certificate for survodutide looks like
Every batch we release carries an independent certificate of analysis, and the figures are transcribed on the product page and in the certificate register. For an unlicensed development compound the certificate has to carry more of the weight, because there is no public reference standard to check it against.
Purity by RP-HPLC. Reversed-phase HPLC on a C18 column with UV detection at 214 or 220 nm, reporting the main peak as a percentage of all integrated peaks. A good batch shows a single dominant peak at 98% or above. Lipidated peptides can show a small late-eluting shoulder from the lipid chain's own heterogeneity; a large early-eluting peak is more likely a truncated sequence.
Identity by LC-MS. The certificate must state the sequence and the expected mass it tested against, and the deconvoluted observed mass should agree with that figure to within a few tenths of a dalton. Because survodutide's identifiers are not standardised in public databases, a certificate that quotes only "conforms" without a mass is not adequate for this compound.
Net peptide content. The lyophilised powder contains bound water and trifluoroacetate counter-ions, so the peptide fraction by mass should be reported where available.
Endotoxin. Where tested, a LAL result in endotoxin units per milligram, which matters for cell-based assays.
Our guide to reading a certificate of analysis goes through a complete report line by line.
Related compounds
Survodutide belongs to the group of proglucagon-family peptides that are compared with one another in the clinical literature. Mazdutide is the other glucagon/GLP-1 dual agonist in the catalogue, built on oxyntomodulin rather than glucagon. GLP-3 (retatrutide) adds the GIP receptor to make a triple agonist. Tirzepatide is the GIP/GLP-1 co-agonist that is silent at the glucagon receptor, and semaglutide is the selective GLP-1 comparator. The structural and pharmacological differences across the family are set out in our GLP-1 family comparison.
Frequently asked questions
How does survodutide differ from mazdutide? Both are glucagon/GLP-1 dual agonists, but survodutide is built on the glucagon sequence and mazdutide on oxyntomodulin, and they come from different developers with different lipidation chemistry. Their receptor potency ratios differ, which is why the clinical profiles are not identical.
Is survodutide licensed anywhere? No. It is in phase 3 trials for obesity and for MASH and has no marketing authorisation.
Why does the certificate not quote a CAS number? Development compounds do not always have a CAS registration in general use, and where one exists it may not be the one printed by suppliers. The sequence and mass on the certificate are the reliable identifiers.
Does the research material contain the clinical formulation's excipients? No. It is the lyophilised peptide, usually as a trifluoroacetate salt, without buffers or preservatives.
References
- Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCG/GLP-1 receptor dual agonist with robust anti-obesity efficacy. Molecular Metabolism. 2022;66:101633. doi:10.1016/j.molmet.2022.101633.
- le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology. 2024;12(3):162–173. doi:10.1016/S2213-8587(23)00356-X.
- Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. New England Journal of Medicine. 2024;391(4):311–319. doi:10.1056/NEJMoa2401755.
This monograph summarises the published literature for laboratory researchers. It is not medical advice, and nothing on this site is for human or veterinary use.